17 employees
EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.
2022
$50M
from 3 investors over 3 rounds
EpiBiologics raised $50M on March 22, 2023
Investors: Polaris Partners, GV and Vivo Capital